International Study Assesses Current Trends in Luspatercept Use for MDS

By Andrew Moreno - Last Updated: July 2, 2024

Luspatercept has entered use as a treatment for lower-risk myelodysplastic syndrome (LR-MDS), but researchers still lack a clear picture of how it is currently being used or in which patients. An international study presented at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain, brought real world data to address this question.

Advertisement

The study was a noninterventional, retrospective medical records review conducted in three countries, based on data collected through November 2023. It involved a total of 114 adult patients, with 56 from Germany, 52 from Spain, and six from Canada. The cohort was 59.6% male, 92.1% white, and its median age was 71 years.

Among 111 patients with available data, 64.9% had a Revised International Prognostic Scoring System (IPSS-R) risk status of “very low” or “low” at the time they received an LR-MDS diagnosis. Out of 65 patients with available data, 53.8% had an IPSS-R risk status of “very low” or “low” at the time they began luspatercept. 76 patients had received treatment before luspatercept, of whom 94.7% had used an erythropoietin-stimulating agent.

Luspatercept was most often used by the study cohort as second-line LR-MDS therapy, followed by as first-line, and then as third-line or later (57.9%; 33.3%; 8.8%). Patients initiated this therapy a median of 10.7 months after their diagnosis, but a median of only 0.9 months when used as first-line therapy. The median duration of therapy was 8.7 months.

There were 103 patients for whom luspatercept dosing data were available. Among them, the median dose at initiation was 1mg/kg/administration and 91.3% received a thrice weekly cycle. Out of the total cohort of 114 patients, 17.5% received a dose increase. As of their last follow-up, 17 of the patients who had a dose increase had a median dose of 1.3 mg/kg/administration, cycled every three weeks.

Among the total cohort of 114 patients, 14.9% discontinued luspatercept therapy. Dosing information was available for 15 of these patients, and of those patients, 40% had escalated their dosing before they discontinued luspatercept.

Reference

Díez Campelo M, Yucel A, Goyal RK, et al. Luspatercept utilization patterns in lower-risk myelodysplastic syndrome (LR-MDS): Findings from a multinational medical record review study. Abstract P1909. Presented at the European Hematology Association 2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.

Post Tags:EHA 2024
Advertisement
Advertisement
Advertisement